Form 8-K - Current report:
SEC Accession No. 0001493152-24-027217
Filing Date
2024-07-15
Accepted
2024-07-15 06:15:32
Documents
14
Period of Report
2024-07-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45196
2 ex10-2.htm EX-10.2 59655
  Complete submission text file 0001493152-24-027217.txt   294991

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qlgn-20240712.xsd EX-101.SCH 3009
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qlgn-20240712_lab.xml EX-101.LAB 34240
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qlgn-20240712_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3691
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 241115808
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)